World journal of virology · 2026
Characterization of human immunodeficiency virus drug-resistance mutations among individuals with low-level-viremia in low-income and middle-income countries: A meta-analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
El-Imam Ibrahim Ahmed, Chenya Upendo Kayeke, Mbishi Jackline Vicent, Peter Timothy Antipas, Mpimo Beatrice Kelvin, Ndembi Nicaise, Bakari Hafidha Mhando, Mbwana Mariam Salim, Fussi Hassan Fredrick, Ally Haji Mbwana, Dababneh Sanad Wael, Ramadhani Habib Omari
Аннотация
BACKGROUND: Low-level viremia (LLV) defined as [human immunodeficiency virus (HIV)-RNA 51-999 copies/mL] has been associated with an increased risk of drug resistance and treatment failure. Advances in next-generation sequencing enabled the detection of drug resistance mutations (DRM) among people with LLV. However, evidences remain limited in low-income and middle-income countries (LMIC) where surveillance is most needed to inform global epidemic control strategies.
AIM: To determine the prevalence of HIV DRM among people living with HIV who have LLV in low- and middle-income countries.
METHODS: PubMed, Cochrane Library, and EMBASE were systematically searched for articles published between January 2015 and May 2025. Studies were included if they reported DRM among adolescents and/or adults with LLV in LMIC. Mutations were interpreted using Stanford University HIV Drug Resistance Database. Prevalence of DRM was computed as the proportion of resistance mutations among successfully sequenced samples. Pooled estimates of resistance mutation and 95%CI were calculated using random-effects models with stratified analyses comparing mutations by geographic location (Africa vs Asia).
RESULTS: Twenty studies including 7613 people with LLV were included. Of these, 5252 (73.9%) had their samples successfully sequenced. Eleven studies were from Africa and nine from Asia. Overall, the pooled prevalence of DRM was 50.4% (95%CI: 38.3-62.5) with a significantly higher prevalence observed among Africa studies compared to Asia's (58.0% vs 40.7%; P < 0.0001). The prevalence of mutations associated with nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitor were 44.6% (95%CI: 34.8-54.4), and 50.9% (95%CI: 41.4-60.4) respectively and were significantly higher in Africa than in Asia. Protease inhibitor associated mutations were also common in Africa than in Asia (7.3% vs 4.1%; P < 0.001), though the overall prevalence remains low.
CONCLUSION: Most individuals with LLV have resistance mutations and remain on a failed regimen over an extended period. Because resistance testing is not routinely performed in LMIC, lowering the viral failure threshold may improve timely switching to effective regimens, preserve treatment options, and reduce resistance accumulation in high HIV burden regions.
AIM: To determine the prevalence of HIV DRM among people living with HIV who have LLV in low- and middle-income countries.
METHODS: PubMed, Cochrane Library, and EMBASE were systematically searched for articles published between January 2015 and May 2025. Studies were included if they reported DRM among adolescents and/or adults with LLV in LMIC. Mutations were interpreted using Stanford University HIV Drug Resistance Database. Prevalence of DRM was computed as the proportion of resistance mutations among successfully sequenced samples. Pooled estimates of resistance mutation and 95%CI were calculated using random-effects models with stratified analyses comparing mutations by geographic location (Africa vs Asia).
RESULTS: Twenty studies including 7613 people with LLV were included. Of these, 5252 (73.9%) had their samples successfully sequenced. Eleven studies were from Africa and nine from Asia. Overall, the pooled prevalence of DRM was 50.4% (95%CI: 38.3-62.5) with a significantly higher prevalence observed among Africa studies compared to Asia's (58.0% vs 40.7%; P < 0.0001). The prevalence of mutations associated with nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitor were 44.6% (95%CI: 34.8-54.4), and 50.9% (95%CI: 41.4-60.4) respectively and were significantly higher in Africa than in Asia. Protease inhibitor associated mutations were also common in Africa than in Asia (7.3% vs 4.1%; P < 0.001), though the overall prevalence remains low.
CONCLUSION: Most individuals with LLV have resistance mutations and remain on a failed regimen over an extended period. Because resistance testing is not routinely performed in LMIC, lowering the viral failure threshold may improve timely switching to effective regimens, preserve treatment options, and reduce resistance accumulation in high HIV burden regions.